Molecular Formula | C15H30N4O5 |
Molar Mass | 346.4225 |
Solubility | DMSO 0.2 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
MDL | MFCD22417093 |
In vivo study | Peramivir protected mice against infection with highly pathogenic avian influenza, and multiple-dose treatment was effective in ferrets. The performance of Peramivir in combination with Oseltamivir was better than that of each compound alone in the treatment of influenza infection in mice. Peramivir(30 mg/kg) can effectively promote the survival of mice infected with systemic replication H5N1 virus. Peramivir was protective in 30% of H1N1 virus mice at a dose of 0.5 mg/kg/day. But ineffective at lower doses when used as monotherapy. The combination of Peramivir and favipiravir can increase the cell survival rate, Peramivir at 0.025 mg/kg/day, 0.05 mg/kg/day, A dose of 0.1 mg/kg/day and a combination of 40 mg/kg/day Favipiravir increased cell survival by 10-50%. The combination of Peramivir and favipiravir resulted in increased lifespan, improved body weight and pulmonary hemorrhage scores and significant reductions in lung weight in H1N1-infected mice (1 mg/kg/day). And Rimantadine (5 mg/kg/day to 10 mg/kg/day) resulted in body weight loss of 1.69 and 0.69, respectively, whereas in A mouse model of sublethal influenza A(H3N2) virus, peramivir (3 mg/kg/day) and Rimantadine (10 mg/kg/day to 30 mg/kg/day) did not show any weight loss. |